Trial Profile
A Phase II Trial of Orally Administered CAI for Patients With Persistent or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2013
Price :
$35
*
At a glance
- Drugs L 651582 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 03 Jul 2013 New trial record
- 03 Jul 2013 New trial record